Live Breaking News & Updates on Karim Dabbagh

Stay updated with breaking news from Karim dabbagh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting

Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing ....

Karim Dabbagh , Jean Marie Lefebvre , Jean Volatier , Bpifrance Investissement , Nadia Kamal , Kepler Cheuvreux , Claude Bertrand , Senior Pr Corporate Communications , Company Universal Registration Document , Trophic Communications , Regulatory News , Microbiome Ecosystem , Extraordinary General Meeting , Seventure Partners , Chief Executive Officer , Annual General Meeting , Universal Registration , General Meeting , Maat Pharma , Microbiome Ecosystem Therapies , Euronext Paris , Investor Relations , Communications Manager , Ihr Portfolio ,

MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros

Regulatory News:

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR. ....

United Kingdom , United States , Karim Dabbagh , Bpifrance Investissement , Financial Services , Company Board Of Directors On , European Parliament , French Financial Markets Authority Autorit , Regulatory News , Microbiome Ecosystem , Primary Offering , Seventure Partners , Offering Price , Reserved Offering , Maat Pharma , Global Offering , French Commercial Code , French Monetary , Financial Code , Selling Shareholder , Euronext Paris , Chief Executive Officer , Ordinary Shares , Existing Share Capital , Enlarged Share Capital , Mutuel Innovation ,

May 15, 2024: MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros

May 15, 2024: MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Bpifrance Investissement , Karim Dabbagh , European Parliament , Company Board Of Directors On , French Financial Markets Authority Autorit , Maat Pharma , Microbiome Ecosystem , Primary Offering , Seventure Partners , Offering Price , Reserved Offering , Global Offering , French Commercial Code , French Monetary , Financial Code , Selling Shareholder , Euronext Paris , Chief Executive Officer , Ordinary Shares , Existing Share Capital , Enlarged Share Capital , Mutuel Innovation , Jean Marie Lef , Placement Agents , Global Coordinator , Joint Bookrunner ,

MaaT Pharma Announces New Appointments to the Board and Executive Team

MaaT Pharma Announces New Appointments to the Board and Executive Team
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nadia Kamal , Emilie Plantamura , Karim Dabbagh , Guilhaume Debroas , Kepler Cheuvreux , Gervais Tougas , Philippe Moyen , Therapeutics Inc , Head Of Clinical Development , Corporate Communications , Trophic Communications , Second Genome Inc , Company As Head Of Investor Relations , Company Universal Registration Document , Senior Pr Corporate Communications , Chief Medical Officer , Chief Operating , Microbiome Ecosystem , Jean Marie Lef , Innovation Divisions , Harmonie Mutuelle , Corporate Social Responsibility , Early Access , Marie Lef , Maat Pharma , Professor Gervais Tougas ,

Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration

/PRNewswire/ Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers,. ....

Susannah Cantrell , Karim Dabbagh , Arena Pharmaceuticals , Gilead Sciences Inc , Second Genome , Chief Executive Officer , Chief Operating Officer , Chief Business Officer , Gilead Sciences ,